Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover Study of Ribociclib (LEE011) in Patients Continuing to Benefit From Treatment
NCT02934568Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2016
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of ribociclib in solid tumor (advanced stage), sponsored by Novartis. Primary endpoints: Number of Patients enrolled and received LEE011 up to 5 years and Length of time receiving study treatment up to 5 years. Started Dec 2016; status: active, not recruiting.
02
Drugs
ribociclib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02934568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02934568.